DK1401837T3 - Purinderivater som A2B-adenosinreceptorantagonister - Google Patents

Purinderivater som A2B-adenosinreceptorantagonister

Info

Publication number: DK1401837T3
Authority: DK; Denmark
Prior art keywords: optionally substituted; receptor antagonists; adenosine receptor; purine derivatives; sup
Prior art date: 2001-06-29

Application number

DK02749704T

Other languages

English (en)

Inventor

Jeff A Zablocki

Venkata Palle

Vaibhav Varkhedkar

Dengming Xiao

Original Assignee

Cv Therapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-06-29

Filing date

2002-06-27

Publication date

2005-11-07

2002-06-27 Application filed by Cv Therapeutics Inc filed Critical Cv Therapeutics Inc

2005-11-07 Application granted granted Critical

2005-11-07 Publication of DK1401837T3 publication Critical patent/DK1401837T3/da

Links

229940121359 adenosine receptor antagonist Drugs 0.000 title abstract 2
239000000296 purinergic P1 receptor antagonist Substances 0.000 title abstract 2
101150078577 Adora2b gene Proteins 0.000 title 1
229940083251 peripheral vasodilators purine derivative Drugs 0.000 title 1
150000003212 purines Chemical class 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 2
206010012689 Diabetic retinopathy Diseases 0.000 abstract 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
125000003342 alkenyl group Chemical group 0.000 abstract 1
125000002947 alkylene group Chemical group 0.000 abstract 1
125000000304 alkynyl group Chemical group 0.000 abstract 1
208000006673 asthma Diseases 0.000 abstract 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
150000002148 esters Chemical class 0.000 abstract 1
125000001072 heteroaryl group Chemical group 0.000 abstract 1
125000000623 heterocyclic group Chemical group 0.000 abstract 1
229910052760 oxygen Inorganic materials 0.000 abstract 1
239000001301 oxygen Substances 0.000 abstract 1
229940002612 prodrug Drugs 0.000 abstract 1
239000000651 prodrug Substances 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
125000005017 substituted alkenyl group Chemical group 0.000 abstract 1
125000000547 substituted alkyl group Chemical group 0.000 abstract 1
125000004426 substituted alkynyl group Chemical group 0.000 abstract 1
125000003107 substituted aryl group Chemical group 0.000 abstract 1
125000005346 substituted cycloalkyl group Chemical group 0.000 abstract 1
229910052717 sulfur Inorganic materials 0.000 abstract 1
239000011593 sulfur Chemical group 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pulmonology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Psychology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)

DK02749704T 2001-06-29 2002-06-27 Purinderivater som A2B-adenosinreceptorantagonister DK1401837T3 (da)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US30220801P	2001-06-29	2001-06-29

Publications (1)

Publication Number	Publication Date
DK1401837T3 true DK1401837T3 (da)	2005-11-07

Family

ID=23166757

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK02749704T DK1401837T3 (da)	2001-06-29	2002-06-27	Purinderivater som A2B-adenosinreceptorantagonister

Country Status (10)

Country	Link
US (2)	US6770651B2 (da)
EP (1)	EP1401837B1 (da)
JP (1)	JP4335000B2 (da)
KR (2)	KR100883292B1 (da)
AT (1)	ATE307132T1 (da)
CA (1)	CA2451244C (da)
DE (1)	DE60206756T2 (da)
DK (1)	DK1401837T3 (da)
ES (1)	ES2247356T3 (da)
WO (1)	WO2003002566A1 (da)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ITRM20010465A1 (it) *	2001-07-31	2003-01-31	Sigma Tau Ind Farmaceuti	Derivati della triazolil-imidazopiridina e delle triazolilpurine utili come ligandi del recettore a2a dell'adenosina e loro uso come medicam
ATE355291T1 (de) *	2001-12-18	2006-03-15	Cv Therapeutics Inc	A2a adenosinrezeptorantagonisten
DE60322748D1 (de) *	2003-05-06	2008-09-18	Cv Therapeutics Inc	Xanthinderivate als a2b-adenosinrezeptorantagonisten
NL1023355C2 (nl) *	2003-05-07	2004-11-09	Oce Tech Bv	Hot melt inkt omvattend een mengsel van kleurstoffen.
TWI372050B (en)	2003-07-03	2012-09-11	Astex Therapeutics Ltd	(morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
EP1646390B1 (en) *	2003-07-22	2008-10-08	Cv Therapeutics, Inc.	A1 adenosine receptor antagonists
WO2005047268A2 (en) *	2003-11-10	2005-05-26	X-Ceptor Therapeutics, Inc.	Substituted pyrimidine compositions and methods of use
WO2005058898A2 (en) *	2003-12-16	2005-06-30	Ranbaxy Laboratories Limited	Purine compounds which can be used as phosphodiesterase (pde) type iv inhibitors
EP1833819A1 (en)	2004-12-30	2007-09-19	Astex Therapeutics Limited	Pyrazole compounds that modulate the activity of cdk, gsk and aurora kinases
ES2270715B1 (es)	2005-07-29	2008-04-01	Laboratorios Almirall S.A.	Nuevos derivados de pirazina.
ES2577514T3 (es)	2005-08-22	2016-07-15	The Regents Of The University Of California	Antagonistas de TLR
WO2007030438A2 (en) *	2005-09-06	2007-03-15	Pharmacopeia, Inc.	Aminopurine derivatives for treating neurodegenerative diseases
ES2274712B1 (es) *	2005-10-06	2008-03-01	Laboratorios Almirall S.A.	Nuevos derivados imidazopiridina.
EP1968579A1 (en)	2005-12-30	2008-09-17	Astex Therapeutics Limited	Pharmaceutical compounds
EP2029597A4 (en) *	2006-05-31	2011-11-23	Univ California	purine analogs
EP2049119A2 (en)	2006-06-29	2009-04-22	Astex Therapeutics Limited	Pharmaceutical combinations of 1-cyclopropyl-3-[3-(5-morphoolin-4-ylmethyl-1h-benzoimidazol-2-yl)-1h-1-pyrazol-4-yl]-urea
US7470697B2 (en) *	2006-09-01	2008-12-30	Adenosine Therapeutics, Llc	Pyrrolo[3,2-D] pyrimidines that are selective antagonists of A2B adenosine receptors
ES2552471T3 (es)	2007-02-07	2015-11-30	The Regents Of The University Of California	Conjugados de agonistas de TLR sintéticos y usos de los mismos
JP2011500716A (ja) *	2007-10-16	2011-01-06	ギリアード・パロ・アルト・インコーポレイテッド	Ａ３アデノシン受容体アンタゴニスト
EA201001264A1 (ru) *	2008-02-07	2011-04-29	Дзе Регентс Оф Дзе Юниверсити Оф Калифорния	Способ лечения заболеваний мочевого пузыря с помощью активатора tlr7
EP2268641B1 (en)	2008-03-26	2014-09-03	Advinus Therapeutics Pvt. Ltd.	Heterocyclic compounds as adenosine receptor antagonist
JP2011528364A (ja) *	2008-07-16	2011-11-17	キング・ファーマシューティカルズ・リサーチ・アンド・デベロプメント・インコーポレイティッド	アテローム性動脈硬化症の治療
KR20110117705A (ko)	2009-02-11	2011-10-27	더 리전트 오브 더 유니버시티 오브 캘리포니아	톨-유사 수용체 조정제 및 질병의 치료
JP5765239B2 (ja)	2009-03-13	2015-08-19	アドヴィナス・セラピューティックス・リミテッド	置換縮合ピリミジン化合物
HRP20150766T1 (hr) *	2009-03-20	2015-08-14	Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.	Oksidirani derivati triazolilpurina, korisni kao ligandi adenozinskog receptora a2a, te namijenjeni upotrebi kao medikamenti
JP5843778B2 (ja) *	2009-11-09	2016-01-13	アドヴィナス・セラピューティックス・リミテッド	置換縮合ピリミジン化合物、その調製およびその使用
BR112012032766A2 (pt)	2010-06-30	2019-09-24	Gilead Sciences Inc	uso de antagonistas do receptor de adenosina a2b para o tratamento da hipertensão pulmonar
CN103261200B (zh)	2010-09-13	2016-03-30	阿迪维纳斯疗法有限公司	作为a2b腺苷受体拮抗剂的前药的嘌呤化合物、它们的制备方法及医药用途
DE102011005232A1 (de)	2011-03-08	2012-09-13	AristoCon GmbH & Co. KG	Adenosin und seine Derivate zur Verwendung in der Schmerztherapie
AR085942A1 (es)	2011-04-07	2013-11-06	Gilead Sciences Inc	Uso de receptor de aadenosina para tratar la insuficiencia cardiaca y la arritmia en pacientes posinfarto de miocardio
CA2969587A1 (en) *	2014-12-05	2016-06-09	Centre National De La Recherche Scientifique (Cnrs)	Compounds for treating cystic fibrosis
WO2017188287A1 (ja) *	2016-04-26	2017-11-02	大日本住友製薬株式会社	置換プリン誘導体
US11697851B2 (en)	2016-05-24	2023-07-11	The Regents Of The University Of California	Early ovarian cancer detection diagnostic test based on mRNA isoforms
PE20220166A1 (es) *	2019-03-05	2022-01-28	F Star Therapeutics Inc	Compuestos, composiciones y metodos para el tratamiento de enfermedad
WO2024105159A1 (en) *	2022-11-16	2024-05-23	University Of Zurich	Ligands of the m6a-rna readers

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4954504A (en) *	1986-11-14	1990-09-04	Ciba-Geigy Corporation	N9 -cyclopentyl-substituted adenine derivatives having adenosine-2 receptor stimulating activity
US6545002B1 (en)	1999-06-01	2003-04-08	University Of Virginia Patent Foundation	Substituted 8-phenylxanthines useful as antagonists of A2B adenosine receptors
EP1208100B1 (en) *	1999-08-31	2003-04-02	Vanderbilt University	Selective antagonists of a2b adenosine receptors
ITRM20010465A1 (it) *	2001-07-31	2003-01-31	Sigma Tau Ind Farmaceuti	Derivati della triazolil-imidazopiridina e delle triazolilpurine utili come ligandi del recettore a2a dell'adenosina e loro uso come medicam
US6897208B2 (en) *	2001-10-26	2005-05-24	Aventis Pharmaceuticals Inc.	Benzimidazoles
ATE355291T1 (de) *	2001-12-18	2006-03-15	Cv Therapeutics Inc	A2a adenosinrezeptorantagonisten

2002
- 2002-06-27 DE DE60206756T patent/DE60206756T2/de not_active Expired - Lifetime
- 2002-06-27 WO PCT/US2002/020631 patent/WO2003002566A1/en not_active Ceased
- 2002-06-27 KR KR1020037017083A patent/KR100883292B1/ko not_active Expired - Lifetime
- 2002-06-27 JP JP2003508947A patent/JP4335000B2/ja not_active Expired - Lifetime
- 2002-06-27 EP EP02749704A patent/EP1401837B1/en not_active Expired - Lifetime
- 2002-06-27 ES ES02749704T patent/ES2247356T3/es not_active Expired - Lifetime
- 2002-06-27 KR KR1020087020714A patent/KR100897219B1/ko not_active Expired - Lifetime
- 2002-06-27 CA CA2451244A patent/CA2451244C/en not_active Expired - Lifetime
- 2002-06-27 AT AT02749704T patent/ATE307132T1/de active
- 2002-06-27 US US10/184,494 patent/US6770651B2/en not_active Expired - Fee Related
- 2002-06-27 DK DK02749704T patent/DK1401837T3/da active
2004
- 2004-04-30 US US10/837,290 patent/US7238700B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
WO2003002566A1 (en)	2003-01-09
KR100883292B1 (ko)	2009-02-11
JP2004536102A (ja)	2004-12-02
CA2451244C (en)	2012-01-17
DE60206756T2 (de)	2006-07-13
HK1064096A1 (en)	2005-01-21
EP1401837A1 (en)	2004-03-31
US6770651B2 (en)	2004-08-03
US7238700B2 (en)	2007-07-03
ES2247356T3 (es)	2006-03-01
KR100897219B1 (ko)	2009-05-14
ATE307132T1 (de)	2005-11-15
CA2451244A1 (en)	2003-01-09
US20040209899A1 (en)	2004-10-21
US20030064999A1 (en)	2003-04-03
KR20080081208A (ko)	2008-09-08
EP1401837B1 (en)	2005-10-19
KR20040023634A (ko)	2004-03-18
JP4335000B2 (ja)	2009-09-30
DE60206756D1 (de)	2006-03-02

Publication	Publication Date	Title
DK1401837T3 (da)	2005-11-07	Purinderivater som A2B-adenosinreceptorantagonister
NL300927I1 (nl)	2018-12-04	tivozanib of een zout of hydraat ervan, in het bijzonder het hydrochloride-monohydraat
TR200200985T2 (tr)	2002-10-21	Pürin türevleri
CY1117132T1 (el)	2017-04-05	Παραγωγο θειαζολιου
AP1753A (en)	2007-07-18	Thiophene derivatives as antiviral agents for flavvivirus infection
MXPA04003795A (es)	2004-07-30	Compuestos de pirimidina y composiciones farmaceuticas que contienen los compuestos.
EA200600333A1 (ru)	2006-06-30	Производные индазола
NO20062713L (no)	2006-08-01	2,6 bisheteroaryl-4-aminopyrimidiner som adenosin reseptor antagonister
NO20052496L (no)	2005-06-24	Selekterte CGRP antagonister, fremgangsmater for fremstilling derav og anvendelse derav som medikamenter.
WO2003022216A3 (en)	2003-12-11	Biaryl substituted purine derivatives as potent antiproliferative agents
NO20052493L (no)	2005-05-24	Selekterte CGRP antagonister, fremgangsmater for fremstilling derav og deres anvendelse som farmasoytiske sammensetninger.
TW200740758A (en)	2007-11-01	Benzoquinazoline derivatives
WO2004069133A3 (en)	2004-11-25	N-monoacylated o-phenylenediamines as anti -cancer agents
PT1140851E (pt)	2004-12-31	4-oxo-1,4-di-hidro-3-quinolinacarboxamidas como agentes antivirais
NO20033145L (no)	2003-09-09	Purinderivater som purinergiske reseptorantagonister
DK0784054T3 (da)	2002-03-25	1,2,3,4-tetrahydroquinoxalinderivater og deres anvendelse som glutamatreceptorantagonister
TW333527B (en)	1998-06-11	Benzimidazoles, pharmaceutical compositions containing these compounds and processes for preparing them
WO2003022219A3 (en)	2003-11-13	Biarylamino purine antiproliferative agents
WO2003022805A3 (en)	2004-01-22	Heterocycle substituted purines as antiproliferative agents
WO2003068776A1 (en)	2003-08-21	[1,2,4]TRIAZOLO[1,5-c]PYRIMIDINE DERIVATIVES
EA200400545A1 (ru)	2004-08-26	Новые замещенные 4-фенил-4-[1h-имидазол-2-ил] пиперидиновые производные и их применение в качестве селективных непептидных агонистов дельта-опиоидов
GEP20074058B (en)	2007-03-12	4-(7-halo-2-quino(xa) linyloxy-phenoxy-propionic acid derivatives as antineoplastic agents
ECSP067111A (es)	2007-01-26	Derivados de pirido-pirimidina, su preparación, su aplicación en terapéutica
TW200626145A (en)	2006-08-01	Heterocyclic compounds and thrombopoietin receptor activators
WO2006110884A8 (en)	2006-12-14	2, 6-di (hetero) aryl -4-amido-pyrimidines as adenosine receptor antagonists